The grades of 5 Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
This week, Celgene Corporation (CELG) pushes up from a C to a B rating. Celgene Corporation is a global integrated biopharmaceutical company engaged in the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The company also gets A’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of CELG stock.
Ophthotech Corp. (OPHT) gets a higher grade this week, advancing from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of OPHT stock.
Acorda Therapeutics, Inc. (ACOR) shows solid improvement this week. The company’s rating rises from a C to a B. Acorda Therapeutics, Inc. is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The company also gets A’s in earnings surprise and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ACOR stock.
This week, Affimed N.V.’s (AFMD) ratings are up from a C last week to a B. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of AFMD stock.
CytRx Corporation (CYTR) earns a B this week, jumping up from last week’s grade of C. CytRx Corporation is a biopharmaceutical research and development company that specializes in oncology. For more information, get Portfolio Grader’s complete analysis of CYTR stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
